Arcturus Therapeutics Holdings Inc (ARCT)
16.91
-0.16
(-0.94%)
USD |
NASDAQ |
Nov 22, 16:00
16.94
+0.03
(+0.18%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Enterprise Value: 220.87M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 220.87M |
| November 21, 2024 | 225.20M |
| November 20, 2024 | 200.83M |
| November 19, 2024 | 252.02M |
| November 18, 2024 | 203.53M |
| November 15, 2024 | 196.76M |
| November 14, 2024 | 259.60M |
| November 13, 2024 | 282.36M |
| November 12, 2024 | 293.19M |
| November 11, 2024 | 314.59M |
| November 08, 2024 | 294.41M |
| November 07, 2024 | 270.44M |
| November 06, 2024 | 259.33M |
| November 05, 2024 | 259.88M |
| November 04, 2024 | 245.46M |
| November 01, 2024 | 250.33M |
| October 31, 2024 | 243.02M |
| October 30, 2024 | 260.90M |
| October 29, 2024 | 280.67M |
| October 28, 2024 | 292.86M |
| October 25, 2024 | 276.06M |
| October 24, 2024 | 277.42M |
| October 23, 2024 | 304.50M |
| October 22, 2024 | 298.81M |
| October 21, 2024 | 328.34M |
| Date | Value |
|---|---|
| October 18, 2024 | 335.65M |
| October 17, 2024 | 320.75M |
| October 16, 2024 | 321.56M |
| October 15, 2024 | 330.77M |
| October 14, 2024 | 329.42M |
| October 11, 2024 | 344.04M |
| October 10, 2024 | 321.02M |
| October 09, 2024 | 355.69M |
| October 08, 2024 | 371.40M |
| October 07, 2024 | 409.32M |
| October 04, 2024 | 409.59M |
| October 03, 2024 | 433.42M |
| October 02, 2024 | 452.92M |
| October 01, 2024 | 446.69M |
| September 30, 2024 | 391.44M |
| September 27, 2024 | 335.41M |
| September 26, 2024 | 328.38M |
| September 25, 2024 | 315.94M |
| September 24, 2024 | 327.57M |
| September 23, 2024 | 311.61M |
| September 20, 2024 | 297.01M |
| September 19, 2024 | 308.10M |
| September 18, 2024 | 295.39M |
| September 17, 2024 | 307.83M |
| September 16, 2024 | 297.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
59.67M
Minimum
Mar 22 2023
2.771B
Maximum
Dec 22 2020
528.72M
Average
417.95M
Median
Apr 25 2023
Enterprise Value Benchmarks
| Bioventus Inc | 1.144B |
| Fulcrum Therapeutics Inc | -81.93M |
| Pfizer Inc | 202.30B |
| AIM ImmunoTech Inc | 8.915M |
| Protalix BioTherapeutics Inc | 97.03M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.903M |
| Revenue (Quarterly) | 38.82M |
| Total Expenses (Quarterly) | 49.55M |
| EPS Diluted (Quarterly) | -0.26 |
| Profit Margin (Quarterly) | -17.78% |
| Earnings Yield | -13.13% |
| Normalized Earnings Yield | -12.98 |